Samsara Therapeutics
Christian Behl PhD obtained his PhD in Neurobiology from the Julius Maximilians University of Würzburg. Following post-doctoral research at the Salk Institute for Biological Studies in La Jolla and the Max Planck Institute of Psychiatry in Munich, he became the Head of the Pathobiochemistry Department of the Johannes Gutenberg University (JGU) in Mainz. He has chaired the Institute for Physiological Chemistry and Pathobiochemistry, and the Interdisciplinary Research Centre for Neurosciences (IFZN). Since 2010, he has been the Director of the Institute of Pathobiochemistry of the University Medical Centre (of the JGU) Mainz. Among other honours, he received the Binder Innovation Award of the German Society for Cell Biology (DGZ). Prof Behl’s research interests are in the study of aging cells, neurodegeneration, protein homeostasis and autophagy.
This person is not in the org chart
This person is not in any offices
Samsara Therapeutics
Samsara Therapeutics, Inc. is a biopharmaceutical company aiming to discover the first-in-class therapeutics that treat rare genetic and neurodegenerative diseases and extend a healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy.